Retrospective analysis of factors affecting clinical outcome following CHOP‐based chemotherapy in dogs with primary nodal diffuse large B‐cell lymphoma

Childress, Michael O.; Ramos‐Vara, José A.; Ruple, Audrey

doi:10.1111/vco.12364

Cited by 43 publications

(88 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the majority of dogs relapse with drug-resistant disease and a median progression-free survival times of 252 d are reported. 7 Median overall survival times for canine lymphoma typically range from 10 to 14 months. 8 Subsequent relapses are traditionally treated with varying rescue protocols, though cure is rare.…”

Section: Introductionmentioning

confidence: 99%

Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The gastrointestinal form of lymphoma has a poorer prognosis compared to the multicentric form (Vail et al, 2013). The two prognostic factors, T-cell immunophenotype and substage b are most consistently identified as poor prognostic factors (Childress et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Lymphocyte-to-Monocyte Ratio in Canine High-Grade Lymphoma Cases.

Tagawa¹,

Shimbo²,

Matsumoto³

et al. 2019

jwpr

View full text Add to dashboard Cite

The Lymphocyte-to-Monocyte Ratio (LMR) has been described as a useful prognostic marker for human patients with various cancers and dogs with diffuse large B-cell lymphoma. The objective of this study was to determine whether the LMR could predict disease outcome as measured by the Time To Progression (TTP) and Overall Survival (OS) of dogs with different types of high-grade lymphoma. The medical records of 43 dogs diagnosed with high-grade lymphoma at the Veterinary Medical Center of Obihiro University of Agriculture and Veterinary Medicine between 2013 and 2018, were retrospectively analyzed. Receiver Operating Characteristic (ROC) curve analysis was used to determine the optimal LMR cutoff values. The prognostic influence of the LMR and other clinicopathological data on TTP and OS was studied by Kaplan-Meier curves. To identify the independent prognostic factors, univariate and multivariate Cox proportional analyses were used. The optimal cutoff value of the LMR was 0.7, which corresponded to the maximum sensitivity (0.727) and specificity (0.762) of the LMR for predicting the median days of OS with ROC analysis (area under the curve, 0.794). Log-rank tests showed that dogs with a high LMR had significantly longer TTP and OS than dogs with a low LMR. Moreover, immunophenotype, body weight, treatment regimen and response to treatment were significantly associated with TTP and OS. In multivariate analysis, treatment and response to treatment were independent risk factors for TTP. Moreover, the LMR, treatment regimen and response to treatment were independent predictors of OS.

show abstract

“…Targeted therapy aims to adapt the treatment regimen to the type of neoplasia as well as to the individual patient. The therapeutic effect of specific cytotoxic drug differs among individuals despite the same histological type of lymphoma [9,10,[25][26][27][28]. Therefore, prognostic factors that allow the determination of a predictable response to the treatment protocol remain in the area of clinical interest.…”

Section: Introductionmentioning

confidence: 99%

Study of DNA topoisomerase IIa expression in canine lymphomas and its potential role as a marker of sensitivity to anthracycline-based chemotherapy in dogs

Klimiuk¹,

Łopuszyński

Bulak

et al. 2020

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Introduction. Canine lymphoma remains one of the most chemotherapy-responsive neoplasia in dogs. Many factors affect the prognosis in dogs treated for lymphoma, but indications for a specific treatment regimen in individual animals with lymphoma are poorly defined. Topoisomerase IIa (TOPIIa) is a key enzyme in DNA replication and a molecular target for TOPIIa inhibitors, including anthracyclines. The aim of this study was to determine the expression of TOPIIa in canine malignant lymphomas. The relationship between TOPIIa expression in canine lymphomas and potential sensitivity of neoplastic cells to anthracycline-based chemotherapy is discussed. Materials and method. Samples of formalin-fixed paraffin-embedded lymph nodes from 47 dogs with different subtypes of non-Hodgkin's (34 B-cell and 13 T-cell) lymphoma were immunohistochemically labeled with anti-TOPIIa. The number of positive cells and the intensity of the reaction were taken into account in order to assess TOPIIa expression. Results. TOPIIa expression was evident in all cases, although differences in the number of positive cells and intensity of the reaction were demonstrated between B-cell and T-cell lymphoma groups as well as within individual groups. Based on the established scoring system, in the B-cell lymphoma group statistically higher expression of TOPIIa was found compared to the T-cell lymphoma group (P = 0.006). In B-cell lymphoma group moderate (41.18%) and strong (32.35%) TOPIIa expression predominated, whereas among T-cell lymphoma group the majority were cases with a weak (46.15%) TOPIIa expression. Conclusion. These preliminary results indicate that further studies are needed to determine the prognostic value of TOPIIa expression with regard to the sensitivity of canine B-cell lymphomas to anthracycline-based chemotherapy regimen. Nevertheless, this study indicates the possibility of choosing the appropriate treatment of canine lymphoma based on

show abstract

Retrospective analysis of factors affecting clinical outcome following CHOP‐based chemotherapy in dogs with primary nodal diffuse large B‐cell lymphoma

Cited by 43 publications

References 32 publications

Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma

Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma

Prognostic Value of Lymphocyte-to-Monocyte Ratio in Canine High-Grade Lymphoma Cases.

Study of DNA topoisomerase IIa expression in canine lymphomas and its potential role as a marker of sensitivity to anthracycline-based chemotherapy in dogs

Contact Info

Product

Resources

About